Telbivudine Exhibits No Inhibitory Activity Against HIV-1 Clinical Isolates in Vitro

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2010 Mar 24

PMID 20308377

Citations 5

Authors

Kai Lin

Sylwia Karwowska

Eric Lam

Kay Limoli

Thomas G Evans

Claudio Avila

Affiliations

Soon will be listed here.

Abstract

Most approved drugs with activity against hepatitis B virus (HBV) have activity against human immunodeficiency virus type 1 (HIV-1), which precludes their use in patients who are coinfected with HBV and HIV-1 and who are not receiving antiretroviral therapy due to the risk of inducing resistance. The activity of telbivudine, a highly selective HBV inhibitor, against temporally and geographically distinct wild-type and multidrug-resistant HIV-1 clinical isolates was evaluated in vitro. No inhibition was observed with up to 600 muM drug, which supports further exploration of telbivudine as a therapeutic option for the treatment of HBV infections in patients coinfected with HIV-1.

Citing Articles

Chemical and protein structural basis for biological crosstalk between PPARα and COX enzymes.

Cleves A, Jain A J Comput Aided Mol Des. 2014; 29(2):101-12.

PMID: 25428568 PMC: 4298667. DOI: 10.1007/s10822-014-9815-2.

Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.

Coffin C, Fung S, Ma M Can J Gastroenterol. 2012; 26(12):917-38.

PMID: 23248795 PMC: 3551569. DOI: 10.1155/2012/506819.

Telbivudine exerts no antiviral activity against HIV-1 in vitro and in humans.

van Maarseveen N, Wensing A, De Jong D, Beilhartz G, Obikhod A, Tao S Antivir Ther. 2011; 16(7):1123-30.

PMID: 22024528 PMC: 7732022. DOI: 10.3851/IMP1912.

Review of hepatitis B therapeutics.

Bhattacharya D, Thio C Clin Infect Dis. 2010; 51(10):1201-8.

PMID: 20954965 PMC: 2977969. DOI: 10.1086/656624.

Telbivudine: a review of its use in compensated chronic hepatitis B.

McKeage K, Keam S Drugs. 2010; 70(14):1857-83.

PMID: 20836578 DOI: 10.2165/11204330-000000000-00000.

References

Low E, Cox A, Atkins M, Nelson M . Telbivudine has activity against HIV-1. AIDS. 2009; 23(4):546-7. DOI: 10.1097/QAD.0b013e3283262f09. View

Lin P, Nowicka-Sans B, Terry B, Zhang S, Wang C, Fan L . Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. Antimicrob Agents Chemother. 2008; 52(5):1759-67. PMC: 2346618. DOI: 10.1128/AAC.01313-07. View

Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F . Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS. 2008; 22(12):1399-410. DOI: 10.1097/QAD.0b013e3282f8b46f. View

Domaoal R, McMahon M, Thio C, Bailey C, Tirado-Rives J, Obikhod A . Pre-steady-state kinetic studies establish entecavir 5'-triphosphate as a substrate for HIV-1 reverse transcriptase. J Biol Chem. 2007; 283(9):5452-9. PMC: 7748947. DOI: 10.1074/jbc.M707834200. View

Petropoulos C, Parkin N, Limoli K, Lie Y, Wrin T, Huang W . A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000; 44(4):920-8. PMC: 89793. DOI: 10.1128/AAC.44.4.920-928.2000. View

Benhamou Y, Thibault V, Vig P, Calvez V, Marcelin A, Fievet M . Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol. 2005; 44(1):62-7. DOI: 10.1016/j.jhep.2005.08.020. View

Thio C . Hepatitis B and human immunodeficiency virus coinfection. Hepatology. 2009; 49(5 Suppl):S138-45. DOI: 10.1002/hep.22883. View

Dore G, Cooper D, Barrett C, Goh L, Thakrar B, Atkins M . Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis. 1999; 180(3):607-13. DOI: 10.1086/314942. View

Gish R, Trinh H, Leung N, Chan F, Fried M, Wright T . Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol. 2005; 43(1):60-6. DOI: 10.1016/j.jhep.2005.02.017. View

10.

Alter M . Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2005; 44(1 Suppl):S6-9. DOI: 10.1016/j.jhep.2005.11.004. View

11.

Sheldon J, Corral A, Rodes B, Mauss S, Rockstroh J, Berger F . Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS. 2005; 19(17):2036-8. DOI: 10.1097/01.aids.0000189563.79976.05. View

12.

Standring D, Bridges E, Placidi L, Faraj A, Loi A, Pierra C . Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother. 2001; 12 Suppl 1:119-29. View

13.

Dore G, Cooper D, Pozniak A, DeJesus E, Zhong L, Miller M . Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis. 2004; 189(7):1185-92. DOI: 10.1086/380398. View

14.

Milazzo L, Caramma I, Lai A, Violin M, De Maddalena C, Cesari M . Telbivudine in the treatment of chronic hepatitis B: experience in HIV type-1-infected patients naive for antiretroviral therapy. Antivir Ther. 2009; 14(6):869-72. DOI: 10.3851/IMP1303. View

15.

Wolters L, Niesters H, Hansen B, van der Ende M, Kroon F, Richter C . Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. J Clin Virol. 2002; 24(3):173-81. DOI: 10.1016/s1386-6532(01)00245-1. View

16.

McMahon M, Jilek B, Brennan T, Shen L, Zhou Y, Wind-Rotolo M . The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med. 2007; 356(25):2614-21. PMC: 3069686. DOI: 10.1056/NEJMoa067710. View